This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
So, good morning, everyone. Thanks for joining us. I am Marshall Urist, one of the biotech analysts here at Morgan Stanley and just one piece of business before we get started. Any and all of our research disclosures can be found on any piece of our research or on our website and with that, why don’t we jump in.
We are very happy to be here this morning, with Mike Morrissey, CEO of Exelixis, who I am sure many of you know and before we jump in, this is actually supposed to be open Q&A. So if there any question, please raise your hands and there is microphone circulating.
So with that, Mike, thanks for being here this morning, and maybe to start off, I think it might be useful, you guys just obviously completed a successful and large fundraising. So maybe talk about, give a quick overview for people, where things stand and then we will kind of jump in.
Sounds good. So, again, I will be making forward looking statements this morning. So, please see our SEC filings for a description of the risks that we face in our business. So that’s, right. So we have had a very busy summer and certainly going into a very busy fall.